DUBLIN, August 17, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Melanoma: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis" report to their offering.
Immune checkpoint inhibitors Yervoy, Opdivo, and Keytruda will be the key drivers of growth in the melanoma market.
This report addresses the following questions:
- How will the patent expiries of key brands impact melanoma market sales?
- What will differentiate immune checkpoint inhibitors such as Yervoy, Opdivo, and Keytruda from the rest of the marketed therapies for melanoma?
- Which marketed drugs or combination therapies will dominate the BRAF mutation-positive melanoma segment?
- Considering its cost and safety profile, what is the commercial potential of Imlygic?
- Which pipeline drugs address the unmet needs of NRAS mutation-positive melanoma patients?
Key Topics Covered:
FORECAST: MELANOMA
- Executive Summary
- Market Overview and Trends
- Pricing and Reimbursement
- Market Definition and Methodology
- binimetinib
- Cotellic (cobimetinib),
- encorafenib
- Imlygic (talimogene laherparepvec)
- Keytruda (pembrolizumab),
- Mekinist (trametinib),
- Opdivo (nivolumab)
- Tafinlar (dabrafenib)
- Yervoy (ipilimumab)
- Zelboraf (vemurafenib)
- Primary Research Methodology
TREATMENT: MELANOMA
- Executive Summary
- Primary Research Methodology.
- Disease Definition and Diagnosis,
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends
EPIDEMIOLOGY: MELANOMA
- Executive Summary
- Disease Background
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations
MARKETED DRUGS: MELANOMA
- Executive Summary
- Product Overview
- Product profile: Cotellic
- Product profile: Imlygic
- Product profile: Keytruda
- Product profile: Mekinist
- Product profile: Opdivo
- Product profile: Tafinlar
- Product profile: Yervoy
- Product profile: Zelboraf
PIPELINE: MELANOMA
- Executive Summary
- Clinical Pipeline Overview
- Product profile (late stage): binimetinib
- Product profile (late stage): encorafenib
For more information about this report visit http://www.researchandmarkets.com/research/kbl8bx/melanoma
Related Topics: Skin Cancer Drugs
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article